Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · IEX Real-Time Price · USD
8.44
-0.55 (-6.12%)
Apr 30, 2024, 4:00 PM EDT - Market closed
Theravance Biopharma Revenue
In the year 2023, Theravance Biopharma had annual revenue of $57.42M with 11.84% growth. Revenue in the quarter ending December 31, 2023 was $17.57M with 19.91% year-over-year growth.
Revenue (ttm)
$57.42M
Revenue Growth
+11.84%
P/S Ratio
7.08
Revenue / Employee
$580,040
Employees
99
Market Cap
406.51M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 57.42M | 6.08M | 11.84% |
Dec 31, 2022 | 51.35M | -3.97M | -7.17% |
Dec 31, 2021 | 55.31M | -16.55M | -23.03% |
Dec 31, 2020 | 71.86M | -1.56M | -2.12% |
Dec 31, 2019 | 73.41M | 13.04M | 21.61% |
Dec 31, 2018 | 60.37M | 44.98M | 292.37% |
Dec 31, 2017 | 15.39M | -33.26M | -68.37% |
Dec 31, 2016 | 48.65M | 6.52M | 15.48% |
Dec 31, 2015 | 42.13M | 30.44M | 260.42% |
Dec 31, 2014 | 11.69M | 11.46M | 5,071.68% |
Dec 31, 2013 | 226.00K | -129.92M | -99.83% |
Dec 31, 2012 | 130.15M | 115.29M | 776.16% |
Dec 31, 2011 | 14.85M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Community Health Systems | 12.52B |
Aveanna Healthcare Holdings | 1.90B |
MultiPlan | 961.52M |
CareDx | 280.32M |
Sonida Senior Living | 255.32M |
Pacific Biosciences of California | 200.52M |
Editas Medicine | 78.12M |
C4 Therapeutics | 20.76M |
TBPH News
- 1 day ago - Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 - PRNewsWire
- 20 days ago - Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 - PRNewsWire
- 2 months ago - Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - PRNewsWire
- 2 months ago - Theravance Biopharma to Participate in an Upcoming Investor Conference - PRNewsWire
- 2 months ago - Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 - PRNewsWire
- 4 months ago - Theravance Biopharma's stock slides 21% after Phase 4 trial of COPD treatment fails to meet main goal - Market Watch
- 4 months ago - Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) - PRNewsWire
- 4 months ago - Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors - PRNewsWire